Technological Advances Provide a Fillip to the European IV Therapy and Enteral Nutrition Devices Market, Notes Frost & Sullivan
LONDON, March 1 /PRNewswire/ — The European intravenous (IV) therapy and enteral nutrition devices market currently offers a highly dynamic and lucrative environment. Advances in pharmacology and a wider range of blood products have substantially increased the number of possible drug therapies, which can be used with IV therapy devices. At the same time, developments in biotechnology are rapidly expanding the range of available blood products.
New analysis from Frost & Sullivan (http://www.medicaldevices.frost.com), European IV Therapy and Enteral Nutrition Devices Market, finds that the market earned revenues of $2423.0 million in 2008 and estimates this to reach $2981.2 million in 2012. The following segments are covered in the research: catheters, infusion pumps, administration sets, feeding tubes and feeding pumps.
“IV therapy devices companies are increasingly focusing on developing computer-aided design for their products, resulting in improved and more efficient coordination of procedures,” notes Frost & Sullivan Senior Research Analyst Janani Narasimhan. “Technological advances will not only make the procedures safer but also smarter and more efficient for both IV therapy and enteral nutrition devices.”
IV therapy can be administered at home for patients who do not necessarily need hospital care. European hospitals have recently enforced strict regulations, which have resulted in the introduction of diagnostic related groups (DRGs). This approach focuses solely on downsizing and reducing the time spent by patients in hospitals.
This trend has significantly raised the value of homecare in Europe. In a parallel development, it is now proven that IV therapy can be delivered safely and effectively in patients’ homes. Homecare provides greater independence for patients along with cost-saving benefits, ensuring a win-win situation.
A majority of the European IV therapy and enteral nutrition devices market is held by a few tier-one and tier-two participants. This highly concentrated market implies intense competition. Accordingly, market entry is difficult. This acts as a major restraint as potential participants are being driven out of the market. The end result is market stagnation and dynamism.
“The declining prices of IV therapy and enteral devices are chiefly due to bulk purchases and tenders,” adds Narasimhan. “Often manufacturers bundle together products which results in the slashing of prices. It is not always possible for smaller companies to reduce their prices and hence might lead to further market consolidation.”
The medical devices sector has been on a bull run for the past few years, matching, if not frequently, exceeding growth expectations. No other sector within healthcare has performed as consistently and successfully as medical devices.
Medical device companies grew their aggregate top line at an annual rate of eleven per cent. In the context of higher-end medical devices (which contribute substantially towards the total market revenue), physician’s ability to perform certain procedures is often linked to the device itself. Most of these devices are used in high-acuity setting and hence, cannot be ignored.
“Companies that manufacture devices to treat life-threatening conditions will continue to be immune to the recent economic tensions,” concludes Narasimhan. “Currently, the underlying demand for medical devices will lead to a comparatively smooth business cycle and the market will, in all probability, continue its strong lead.”
European IV Therapy and Enteral Nutrition Devices Market is part of the Medical Devices Growth Partnership Service programme, which also includes research in the following markets: Western European Markets for Percutaneous Coronary Intervention (PCI) Devices, Medical Devices Industry: Trends During the Recession, Western European Markets for Wound Closure and, Medical Device Company Profiles. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.
If you are interested more information on the Frost & Sullivan study European IV Therapy and Enteral Nutrition Devices Market, please send an e-mail to Katja Feick, Corporate Communications, at firstname.lastname@example.org, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.
European IV Therapy and Enteral Nutrition Devices Market M456 Contact: Katja Feick Corporate Communications - Europe P: +49 (0) 69 7703343 E: email@example.com http://www.frost.com Twitter: twitter.com/frost_sullivan
SOURCE Frost & Sullivan